Conatus Pharmaceuticals

About:

Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.

Website: http://www.conatuspharma.com

Top Investors: Advent Life Sciences, MPM Capital, Roche Venture Fund, Aberdare Ventures, Gilde Healthcare

Description:

Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Total Funding Amount:

$62.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)conatuspharma.com

Founders:

Alfred P. Spada, Charles J. Cashion, Jennifer Cayer, Steven J. Mento

Number of Employees:

11-50

Last Funding Date:

2013-06-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai